{"id":35873,"date":"2025-12-22T19:00:00","date_gmt":"2025-12-23T00:00:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/bristol-myers-squibb-company-v-azurity-pharmaceuticals-inc\/"},"modified":"2025-12-30T02:14:07","modified_gmt":"2025-12-30T07:14:07","slug":"bristol-myers-squibb-company-v-azurity-pharmaceuticals-inc","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/bristol-myers-squibb-company-v-azurity-pharmaceuticals-inc\/","title":{"rendered":"Bristol-Myers Squibb Company v. Azurity Pharmaceuticals, Inc."},"content":{"rendered":"<h1><strong>Litigation Summary and Analysis for Bristol-Myers Squibb Company v. Azurity Pharmaceuticals, Inc. | 1:25-cv-01558<\/strong><\/h1>\n<hr \/>\n<h2><strong>Executive Summary<\/strong><\/h2>\n<p>This litigation revolves around patent infringement allegations filed by Bristol-Myers Squibb (BMS) against Azurity Pharmaceuticals in the United States District Court for the District of Delaware (Case No. 1:25-cv-01558). The case presents critical issues related to patent validity, infringement, and potential market exclusivity concerning pharmaceutical formulations. BMS claims Azurity infringed upon specific patented technology, threatening BMS\u2019s commercial rights over a flagship drug.<\/p>\n<p>Key points include:<\/p>\n<ul>\n<li>Nature of the patents involved<\/li>\n<li>Alleged infringing activities by Azurity<\/li>\n<li>Court\u2019s jurisdiction and procedural posture<\/li>\n<li>Strategic implications for both pharmaceutical giants<\/li>\n<li>Potential impact on drug markets<\/li>\n<\/ul>\n<hr \/>\n<h2><strong>1. Case Background and Context<\/strong><\/h2>\n<p><strong>Bristol-Myers Squibb (BMS)<\/strong> is a global biopharmaceutical leader, holding numerous patents covering drug formulations, delivery mechanisms, and manufacturing processes. The specific patent in question, granted in <strong>[year]<\/strong>, pertains to a unique pharmaceutical formulation (details below), granting BMS exclusive manufacturing rights.<\/p>\n<p><strong>Azurity Pharmaceuticals<\/strong> specializes in compounded drugs, often\u2026<\/p>","protected":false},"excerpt":{"rendered":"<p>Litigation Summary and Analysis for Bristol-Myers Squibb Company v. Azurity Pharmaceuticals, Inc. | 1:25-cv-01558 Executive Summary This litigation revolves around [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":34556,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-35873","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/35873","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=35873"}],"version-history":[{"count":0,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/35873\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/34556"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=35873"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=35873"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=35873"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}